SURVIVAL AND CLONAL EVOLUTION IN ESSENTIAL THROMBOCYTHEMIA AND ITS RELATIONSHIP WITH THE MOLECULAR PROFILE AND CYTOREDUCTIVE TREATMENT

EHA Library, Lucia Mezquita, 298033

CHALLENGING DIAGNOSTIC ASSESSMENT OF GERMLINE RUNX1 VARIANTS IN MYELOID MALIGNANCIES: A CASE REPORT OF A PATIENT PRESENTING WITH A NOVEL GERMLINE RUNX1 VARIANT.

EHA Library, Barbara Cauwelier, 298034

CHRONIC MYELOID LEUKEMIA – SO MANY MUTATIONS, BUT BACK TO THE START

EHA Library, Carolina Pavao, 298035

ASXL1 GENE MUTATIONS IN RUSSIAN PATIENTS WITH PH NEGATIVE MYELOPROLIFERATIVE NEOPLASMS

EHA Library, Svetlana Treglazova, 298036

INDIRECT TREATMENT COMPARISON OF THE EFFECT OF FEDRATINIB VERSUS BEST AVAILABLE THERAPY ON SPLEEN VOLUME AND SYMPTOMS FOR PATIENTS WITH MYELOFIBROSIS AND PRIOR RUXOLITINIB TREATMENT

EHA Library, Derek Tang, 298037

ANALYSIS OF A CASE OF ESSENTIAL THROMBOCYTHEMIA WITH CALR MUTATION WHO ACQUIRED ADDITIONAL JAK2 MUTATION IN THE SAME CLONE

EHA Library, Keiki Nagaharu, 298038

TRIPLE-NEGATIVE ESSENTIAL THROMBOCYTHEMIA: NOT PER SE LOW RISK. A CASE SERIES OF 22 PATIENTS

EHA Library, Parvis Sadjadian, 298039

SCORE CHART FOR CARDIOVASCULAR RISK AND JAK2 V617F MUTATIONS IDENTIFIES CHRONIC MYELOPROLIFERATIVE NEOPLASMS PATIENTS AT HIGH RISK FOR THROMBOTIC EVENT

EHA Library, Novella Pugliese, 298040

FIRST CLINICAL DATA OF THE PAN LYSYL OXIDASE INHIBITOR, PXS-5505, TO TREAT MYELOFIBROSIS

EHA Library, Wolfgang Jarolimek, 298041

CHRONIC KIDNEY DISEASE COULD BE A RISK FACTOR FOR THROMBOSIS IN ESSENTIAL THROMBOCYTHEMIA AND POLYCYTHEMIA VERA

EHA Library, Ivan Krecak, 298042

PLATELET AND COAGULATIVE ABNORMALITIES IN POLYCYTHEMIA VERA PATIENTS: THROMBOTIC RISK

EHA Library, EMMA CACCIOLA, 298043

MYELOPROLIFERATIVE NEOPLASM, UNCLASSIFIABLE BY WHO 2008 CLASSIFICATION, IS REALLOCATED TO PREFIBROTIC PMF AND OVERT PMF ACCORDING TO WHO 2016 CLASSIFICATION

EHA Library, Jiwon Yun, 298044

PHASE 2 STUDY OF 9-ING-41, A GLYCOGEN SYNTHASE KINASE 3 BETA (GSK-3Β) INHIBITOR, AS A SINGLE AGENT OR COMBINED WITH RUXOLITINIB, IN PATIENTS WITH MYELOFIBROSIS

EHA Library, Francis Giles, 298045

A CLINICAL AUDIT ON COMPLIANCE WITH BRITISH SOCIETY OF HAEMATOLOGY GUIDELINES FOR DIAGNOSIS AND MANAGEMENT OF PHILADELPHIA NEGATIVE MYELOPROLIFERATIVE NEOPLASMS

EHA Library, Farheen Karim, 298047

CHARACTERISTICS AND FEATURES OF NON-CAUCASIAN MYELOPROLIFERATIVE NEOPLASM PATIENTS IN THE MYMPN REGISTRY

EHA Library, Robyn Scherber, 298048

DOES THE PLATELETS JAK2 V617F ALLELE BURDEN IS AN INDEPENDENT DIAGNOSTIC VALUE IN MPN PATIENTS?

EHA Library, Igor Olkhovskiy, 298049

TRENDS IN OVERALL MORTALITY AMONG US VETERANS WITH INTERMEDIATE / HIGH-RISK PRIMARY MYELOFIBROSIS

EHA Library, Shreekant Parasuraman, 298050

INCREASED RISK OF BCR-ABL1-NEGATIVE MYELOPROLIFERATIVE NEOPLASM IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: A POPULATION-BASED STUDY

EHA Library, Jian Huang, 298051

CDC25C EXPRESSION IN PATIENTS WITH MYELOFIBROSIS IS ASSOCIATED WITH STRONGER MYELOPROLIFERATION AND SHORTER OVERALL SURVIVAL

EHA Library, Davor Galusic, 298052

GENETIC TESTING OF PATIENTS WITH ERYTHROCYTOSIS

EHA Library, Tatiana Subbotina, 298053

PATTERNS OF HYDROXYUREA PRESCRIPTION AND USE IN ROUTINE CLINICAL MANAGEMENT OF POLYCYTHAEMIA VERA: A MULTICENTRE CHART REVIEW STUDY

EHA Library, Tulin Tuglular, 298054

GRAY-ZONE MYELOID NEOPLASMS WITH FEATURES INTERMEDIATE BETWEEN PRIMARY MYELOFIBROSIS AND CHRONIC MYELOMONOCYTIC LEUKEMIA

EHA Library, Yanitsa Davidkova, 298055

HIGHER SERUM URIC ACID IS ASSOCIATED WITH HIGHER RISKS OF THROMBOTIC EVENTS AND DEATH IN PATIENTS WITH PRIMARY MYELOFIBROSIS

EHA Library, Marko Lucijanic, 298056

PILOT TRIAL OF LOW-DOSE CYTARABINE FOR HIGH-RISK PATIENTS WITH POST-POLYCYTHEMIA VERA MYELOFIBROSIS IN UKRAINE

EHA Library, Rostyslav Lozynskyy, 298057

PREDICTORS OF REACTIVE OXYGEN SPECIES LEVELS AND TOTAL ANTIOXIDANT CAPACITY IN ESSENTIAL THROMBOCYTHEMIA

EHA Library, Mihnea-Alexandru Găman, 298058

COMPARISON OF THE STARTING DOSE OF ANAGRELIDE AS A FIRST-LINE THERAPY IN PATIENTS WITH CYTOREDUCTIVE THERAPY-NAÏVE ESSENTIAL THROMBOCYTHEMIA: DIFFERENCE BETWEEN STARTING AT 0.5 AND 1.0 MG/DAY

EHA Library, Yoshinori Hashimoto, 298059

TREATMENT OF SKIN ITCH IN PATIENTS WITH SYSTEMIC MASTOCYTOSIS: ONE CENTER EXPERIENCE

EHA Library, Yury Shatokhin, 298060

THE VALUE OF MPN10 TO ASSESS SYMPTOM BURDEN IN PATIENTS WITH MYELOPROLIFERATIVE NEOPLASMS

EHA Library, Tatyana Ionova, 298061

PROFILE OF RUXOLITINIB AND ITS POTENTIAL INFECTIVE COMPLICATIONS IN THE MYELOFIBROSIS TREATMENT.

EHA Library, Harberth Fernandez - Leyva, 298062

INFLUENCE OF CHEK2 MUTATIONS IN MYELOPROLIFERATIVE NEOPLASM: ONE CENTRE EXPERIENCE

EHA Library, Ruta Dambrauskiene, 298063

PEGYLATED INTERFERON ALFA-2A IS EFFECTIVE AND DECREASES LDH LEVELS IN PATIENTS WITH ESSENTIAL THROMBOCYTHEMIA AND POLYCYTHEMIA VERA

EHA Library, Omer Ekinci, 298064

CLINICAL EXPERIENCE OF SINGLE CENTER IN RUXOLITINIB-TREATMENT OF NON-SELECTIVE GROUP OF PATIENTS WITH PHILADELPHIA-NEGATIVE MYELOPROLIFERATIVE NEOPLASMS

EHA Library, Yulia Chernykh, 298065

MINOR VARIANT FINDER SOFTWARE HELPS TO DETECT OF SOMATIC MUTATIONS IN THE ASXL1 AND JAK2 GENES IN CMN

EHA Library, Tatiana Subbotina, 298066

BENEFITS AND SIDE EFFECTS OF RUXOLITINIB TREATMENT IN ROMANIAN PATIENTS DIAGNOSED WITH MYELOFIBROSIS IN THE FUNDENI CLINICAL INSTITUTE

EHA Library, Iulia Ursuleac, 298067

LONGTERM EFFICACY OF ANAGRELIDE, BASED ON ESSENTIAL THROMBOCYTHEMIA PATIENT REGISTRY

EHA Library, Osman Ilhan, 298068

HOW DOES 2016 WHO CRITERIA FOR POLYCYTHEMIA VERA CONTRIBUTE TO OUR DAILY PRACTICE?: A SINGLE-CENTER STUDY FROM TURKEY

EHA Library, Rafet Eren, 298069

PRIMARY MYELOFIBROSIS- CLINICAL, PATHOLOGICAL AND GENETIC PROFILING- A SINGLE CENTER EXPERIENCE

EHA Library, Sarah Elkourashy, 298070

AMBULATORY MANAGEMENT WITH ORAL ETOPOSIDE (VP-16) IN PATIENTS WITH CHRONIC MYELOMONOCYTIC LEUKEMIA (CMML)

EHA Library, Raquel I. Varela, 298071

PLATELET INDICES PROLIFERATIVE PREDICTIVE ROLE IN ESSENTIAL THROMBOCYTHEMIA

EHA Library, Liri Seraj, 298072

JAK2V617F MUTATION AS A RISK FACTOR FOR HAEMORRHAGIC COMPLICATIONS IN PATIENTS WITH PHILADELPHIA-NEGATIVE MYELOPROLIFERATIVE NEOPLASMS

EHA Library, Evica Simonovic, 298073

BCR-ABL NEGATIVE MYELOPROLIFERATIVE NEOPLASMS: TWO DECADES EXPERIENCE OF A CENTER IN CORDOBA, ARGENTINA.

EHA Library, Daiana Rodriguez, 298074

RUXOLITINIB IN REAL CLINICAL PRACTICE IN MOSCOW CITY CENTER FOR HEMATOLOGY

EHA Library, Maria Pankrashkina, 298075

OCCUPATIONAL EXPOSURE IN HEMATOLOGIC MALIGNANCIES: A SERIES OF CASES

EHA Library, Khouloud TOUIHRI, 298076

INTERFERON ALPHA IN THE TREATMENT OF BCR-ABL1 NEGATIVE MYELOPROLIFERATIVE NEOPLASMS

EHA Library, Catia Reis, 298077

OUTCOMES IN PV AND ET ARE AFFECTED BY AGE, THROMBOSIS, JAK2 STATUS AND SECOND CANCERS: LONG-TERM FOLLOW-UP FROM A DISTRICT GENERAL HOSPITAL.

EHA Library, Luke Attwell, 298078

RELATIONSHIP OF JAK 2 V617F MUTATION ALLELE BURDEN WITH DIFFERENT TREATMENT PROTOCOLS AND SMOKING IN POLISTEMIA VERA CASES

EHA Library, Itir Sirinoglu Demiriz, 298079

HEMATOLOGICAL IMPROVEMENT IN A PATIENT WITH ADVANCED PRIMARY MYELOFIBROSIS TREATED WITH RUXOLITINIB AND DEFERASIROX: A CASE REPORT

EHA Library, Erminia Rinaldi, 298080

JAK2V617F MUTATION AS A RISK FACTOR FOR COMPLICATIONS IN PATIENTS WITH PRIMARY MYELOFIBROSIS

EHA Library, Evica Simonovic, 298081

OUTCOME PREDICTION BY INTERIM PET IN RELAPSED/REFRACTORY CLASSICAL HODGKIN LYMPHOMA RECEIVING THE BEGEV REGIMEN

EHA Library, Carmelo Carlo-Stella, 298082

EARLY HIGH-DOSE SALVAGE AFTER “ABVD X 2 FAILURE” IN HODGKIN’S LYMPHOMA: A PET AND CLINICAL-DRIVEN STRATEGY IN REAL LIFE PRACTICE.

EHA Library, Jacopo Olivieri, 298083

COLLECTION OF PERIPHERAL STEM CELLS IN ADULT HODGKIN'S LYMPHOMA:A STUDY OF RISK FACTORS OF FAILURE

EHA Library, Rym El Fatmi, 298084

IMMUNOTHERAPY WITH NIVOLUMAB IN PATIENTS WITH RELAPSED/REFRACTORY HIV-RELATED LYMPHOMAS

EHA Library, Marina Popova, 298085

THE ROLE OF IMMUNE CHECKPOINT INHIBITORS IN RELAPSED OR REFRACTORY HODGKIN LYMPHOMA AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION.

EHA Library, Anastasiya Beynarovich, 298086

IMPACT OF BODY MASS INDEX (BMI) ON THE OUTCOME OF PATIENTS WITH HODGKIN LYMPHOMA

EHA Library, Talbi Faiza, 298087

CLINICAL AND PROGRESSIVE FEATURES OF PATIENTS WITH AUTOIMMUNE DISEASE ASSOCIATED WITH HODGKIN LYMPHOMA

EHA Library, Talbi Faiza, 298088

EFFECT OF ADULT HODGKIN LYMPHOMA PATIENTS TREATMENT PROCESS ON THEIR RELATIVES

EHA Library, Itir Sirinoglu Demiriz, 298089

INVOLVEMENT OF THE CENTRAL NERVOUS SYSTEM (CNS) IN HODGKIN'S LYMPHOMA (HL)

EHA Library, ABBADI Mohamed Rafik, 298090

LYMPH NODE ACTIVATION ON FDG-PET/CT INDUCED BY INFLUENZA VACCINATION IN HODGKIN LYMPHOMA

EHA Library, Stéphanie Guidez, 298091

SARCOPENIA IN HODGKIN’S LYMPHOMA EVALUATED WITH 18 FDG PET/CT, FOCUS ON AGE, PERFORMANCE AND TREATMENT

EHA Library, Volkan Bas, 298092

PALONOSETRON’S EFFECTIVENESS AS PREVENTION OF CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING IN HODGKIN’S DESEASE TREATED IN FIRST-LINE THERAPY WITH ABVD

EHA Library, Raquel I. Varela, 298093

EVALUATION OF THE PREDICTIVE VALUE OF THE PET SCANNER IN HODGKIN LYMPHOMA AFTER 2 TO 3 CYCLES OF CHEMOTHERAPY

EHA Library, Kahina Belateche, 298094

PROGNOSTIC VALUE OF TISSUE-INFILTRATING IMMUNE CELLS IN TUMOR MICROENVIRONMENT OF FOLLICULAR LYMPHOMA: A SYSTEMATIC REVIEW AND META-ANALYSIS

EHA Library, Mixue Xie, 298095

PRIMARY CUTANEOUS B-CELL INDOLENT LYMPHOMAS – RETROSPECTIVE MULTICENTRIC ANALYSIS

EHA Library, Magdalena Olszewska-Szopa, 298096

FOCAL, SYMPTOMATIC BONE MARROW LESIONS IN WALDENSTRÖM MACROGLOBULINAEMIA CHARACTERISED BY DENSE INFILTRATION WITH LYMPHOPLASMACYTIC LYMPHOMA: A NEWLY DEFINED INDICATION FOR SYSTEMIC TREATMENT

EHA Library, Suzanne Arulogun, 298097

OBINUTUZUMAB PLUS CHEMOTHERAPY IN FOLLICULAR LYMPHOMA RWD.

EHA Library, Kissy Guevara-Hoyer, 298098

EFFICACY AND SAFETY OF ABP 798 COMPARED WITH RITUXIMAB: RESULTS FROM THE COMPARATIVE CLINICAL STUDY IN PATIENTS WITH NON-HODGKIN’S LYMPHOMA

EHA Library, David Chien, 298099

18F-FLUORODEOXYGLUCOSE POSITRON EMISSION TOMOGRAPHY VERSUS BONE MARROW BIOPSY FOR THE EVALUATION OF BONE MARROW INFILTRATION IN NEWLY DIAGNOSED LYMPHOMA PATIENTS: ARE THEY BOTH NECESSARY?

EHA Library, Tania Aguado, 298100

INFORMATIVENESS OF DIFFUSION-WEIGHTED MAGNETIC RESONANCE IMAGING OF THE WHOLE BODY AND POSITRON EMISSION TOMOGRAPHY WITH COMPUTED TOMOGRAPHY FOR FOLLICULAR LYMPHOMA

EHA Library, Ekaterina Nesterova, 298101

ANALYSIS OF THE BONE MARROW INVOLVEMENT IN A GROUP OF PATIENTS WITH FOLLICULAR LYMPHOMA BY COMPARING BONE MARROW BIOPSY AND 18F FDG-PET

EHA Library, Rita S Gomes, 298102

PREVALENCE AND PROGNOSTIC IMPACT OF A POSITIVE SERUM IMMUNOFIXATION IN FOLLICULAR LYMPHOMA PATIENTS

EHA Library, Pablo Mozas, 298103

A MULTI-CENTER RETROSPECTIVE ANALYSIS OF PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA AFTER THIRD-LINE CHEMOTHERAPY

EHA Library, Shigeo Fuji, 298104

OBINUTUZUMAB SHORT DURATION INFUSION IN PREVIOUSLY UNTREATED ADVANCED FOLLICULAR LYMPHOMA: AN ONGOING STUDY

EHA Library, Kai Hübel, 298105

IS PET-CT USEFUL TO IDENTIFY HISTOLOGICAL TRANSFORMATION IN FOLLICULAR LYMPHOMA? A TWO SPANISH CENTRES EXPERIENCE

EHA Library, Miguel Argüello de Tomás, 298106

ARTIFICIAL INTELLIGENCE AGAINST LYMPHOMA : A NEW DEEP LEARNING BASED ANATOMOPATHOLOGY ASSISTANT TO DISTINGUISH FOLLICULAR LYMPHOMA FROM FOLLICULAR HYPERPLASIA

EHA Library, Camille Laurent, 298107

THE ROLE OF RITUXIMAB MAINTENANCE AFTER FRONTLINE THERAPY FOR FOLLICULAR LYMPHOMA

EHA Library, Dulcelena Pires Neves, 298108

PRETREATMENT SERUM ALBUMIN LEVEL IS ASSOCIATED WITH HIGHER RISK OF PD24 IN LATIN AMERICAN PATIENTS WITH FOLLICULAR LYMPHOMA: A STUDY FROM THE LATIN AMERICAN GROUP OF LYMPHOPROLIFERATIVES (GELL)

EHA Library, Maria Alejandra Torres Viera, 298109

OUTCOME OF A 13-YEARS POPULATION-BASED COHORT OF MANTLE CELL LYMPHOMA PATIENTS: ‘REAL-WORLD’ DATA IDENTIFY SUBGROUPS IN NEED OF NEW THERAPIES.

EHA Library, A. Haven, 298110

HEPATITIS C (HCV)-ASSOCIATED LYMPHOMA MARGINAL ZONE (LMZ) – THE EFFECTIVENESS OF DIFFERENT MODES OF ANTIVIRAL THERAPY (AVT).

EHA Library, sergey lepkov, 298111

CAN THE PROGNOSIS OF MANTLE CELL LYMPHOMA BE PREDICTED BY SIMPLE CBC COUNTS?

EHA Library, Handan Haydaroglu Sahin, 298112

T-CELL LARGE GRANULAR LEUKEMIA WITH ATYPICAL IMMUNOPHENOTYPES: A SINGLE CENTER RETROSPECTIVE ANALYSIS OF 17 CASES

EHA Library, Lei Fan, 298113

BENDAMUSTINE DOSE, TREATMENT CYCLES, AND THE IMPACT OF SOLUBLE IL-2R AND LDH VALUES ON BENDAMUSTINE PLUS RITUXIMAB TREATMENT FOR PATIENTS WITH FOLLICULAR LYMPHOMA

EHA Library, Tatsuro Jo, 298114

EVALUATION OF PATIENTS WITH ADULT ONSET LANGERHANS CELL HISTIOCYTOSIS: A SINGLE CENTER EXPERIENCE

EHA Library, Ali Ünal, 298115

INTENSIVE CHEMO-IMMUNOTHERAPY PLUS HEMATOPOIETIC STEM CELL TRANSPLANTATION OR NON-INTENSIVE TREATMENT FOR MANTLE CELL LYMPHOMA -- REAL WORLD CLINICAL OUTCOME IN SINGLE INSTITUTE EXPERIENCE

EHA Library, Tran-Der Tan, 298116

SUBCUTANEOUS RITUXIMAB WITHOUT SPECIFIC PREMEDICATION IS SAFE AND EFFECTIVE FOR PATIENTS WITH NON-HODGKIN LYMPHOMAS: A SINGLE CENTRE EXPERIENCE

EHA Library, Vasileios Pardalis, 298117

IBRUTINIB IN B-CELL LYMPHOMAS AND CHRONIC GRAFT VERSUS HOST DISEASE: A SINGLE CENTER EXPERIENCE

EHA Library, Aysenur Arslan, 298118

THIRTY-FIVE CASES OF WALDENSTRÖM MACROGLOBULINEMIA: TEN YEARS’ EXPERIENCE FROM A SINGLE CENTER

EHA Library, Silvia García Canale, 298119

PROGNOSTIC SIGNIFICANCE OF ABSOLUTE LYMPHOCYTE TO ABSOLUTE MONOCYTE COUNT RATIO IN EGYPTIAN PATIENTS WITH RELAPSED FOLLICULAR LYMPHOMA

EHA Library, Asmaa Mohsen, 298120

SERONEGATIVE MYASTHENIA GRAVIS ASSOCIATED WITH WALDENSTROM'S MACROGLOBULINEMIA

EHA Library, Leena Rahmat, 298121

LYMPHOMATOID GRANULOMATOSIS IN AN IMMUNOCOMPETENT WOMAN

EHA Library, Semra Paydas, 298122

HEMATOLOGY EMERGENCY COMPLICATED BY HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS IN INDOLENT LYMPHOMA

EHA Library, D. Rochate, 298123

FOLLICULAR LYMPHOMA DIAGNOSIS AND TREATMENT IN KOSOVO

EHA Library, Edlira Gashi, 298124

TREATMENT OF INDOLENT B LYMPHOMAS WITH RITUXIMAB : A MONOCENTRIC EXPERIENCE

EHA Library, Wala Ben Kridis, 298125

MANTLE CELL LYMPHOMA DIAGNOSIS AND TREATMENT IN KOSOVO

EHA Library, Adriatik Berisha, 298126

THE HEMOGLOBIN, ALBUMIN, LYMPHOCYTE, AND PLATELET (HALP) SCORE IS A NOVEL SIGNIFICANT PROGNOSTIC FACTOR FOR PATIENTS WITH DIFFUSE LARGE B CELL LYMPHOMA

EHA Library, Vlatka Periša, 298127

R-CHOP CHEMOTHERAPY INCLUDING BIOSIMILAR RITUXIMAB (REDDITUX ®) FOR DE-NOVO DIFFUSE LARGE B-CELL LYMPHOMA PATIENTS: REAL LIFE SINGLE CENTER EXPERIENCE

EHA Library, Murat Ozbalak, 298128

FIRST-LINE THERAPY OF ELDERLY PATIENTS WITH DLBCL - A COMPARISON OF PATIENTS TREATED ON THE RICOVER-60 TRIAL AND PATIENTS TREATED WITH R-CEPIVDSP AT BEIJING UNIVERSITY, CHINA

EHA Library, Shenmiao Yang, 298129

THE IMPACT OF OBESITY ON DIFFUSE LARGE B CELL LYMPHOMA PATIENTS TREATED WITH R-CHOP AT PRINCESS NORAH ONCOLOGY CENTER ,NATIONAL GAURD HOSPITAL.JEDDAH,SAUDI ARABIA.

EHA Library, Alhasan Bajawi, 298130

A BURKITT-LIKE FIRST LINE CHEMO-IMMUNOTHERAPY IS HIGHLY EFFECTIVE IN PATIENTS WITH DIFFUSE LARGE B CELL LYMPHOMAS WITH UNFAVOURABLE BIOLOGICAL FEATURES

EHA Library, Lorenzo Manconi, 298131

TREATMENT OF AGGRESSIVE LYMPHOMA IN PREGNANT WOMEN

EHA Library, Yana MANGASAROVA, 298132

MONOCYTE COUNT, LYMPHOCYTE/MONOCYTE RATIO AND RED CELL DISTRIBUTION WIDTH ARE PROGNOSTIC BIOMARKERS IN PERUVIAN PATIENTS WITH AGGRESSIVE T-CELL LYMPHOMAS

EHA Library, Denisse Castro, 298133